Země: Arménie
Jazyk: angličtina
Zdroj: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
digoxin
Arpimed LLC
C01AA05
digoxin
0,25mg
tablets
(40/1x40/) in blister
Prescription
Registered
2020-09-25
SUMMARY OF PRODUCT CHARACTERISTICS DIGOXIN 0.25 mg Tablets 1. NAME OF THE MEDICINAL PRODUCT Digoxin 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: _ACTIVE INGREDIENT:_ digoxin 0.25 mg _INACTIVE INGREDIENTS: _see 6.1 list of excipient_ _ 3. PHARMACEUTICAL FORM Tablet White flat scored tablets 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Cardiac failure Digoxin is indicated in the management of chronic cardiac failure where the dominant problem is systolic dysfunction. Its therapeutic benefit is greatest in those patients with ventricular dilatation. Digoxin is specifically indicated where cardiac failure is accompanied by atrial fibrillation. Supraventricular arrhythmias Digoxin is indicated in the management of certain supraventricular arrhythmias, particularly chronic atrial flutter and fibrillation. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology: The dose of digoxin for each patient has to be tailored individually according to age, lean body weight and renal function. Suggested doses are intended only as an initial guide. In cases where cardiac glycosides have been taken in the preceding two weeks the recommendations for initial dosing of a patient should be reconsidered and a reduced dose is advised. The difference in bioavailability between injectable digoxin and oral formulations must be considered when changing from one dosage form to another. For example if patients are switched from oral to the I.V. formulation the dosage should be reduced by approximately 33%. Adults and paediatric populations over 10 years Rapid oral loading: If medically appropriate, rapid digitalisation may be achieved in a number of ways, such as 750 to 1500 micrograms (0.75 to 1.5 mg) as a single dose. Where there is less urgency, or greater risk of toxicity e.g. in the elderly, the oral loading dose should be given in divided doses six hours apart, with approximately half the total dose given as the first dose. Clinical response should be assessed before giving each additional dose (see Section 4.4). S Přečtěte si celý dokument